As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...
Boehringer Ingelheim and Eli Lilly and Company announced positive top-line results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction with and without ...
The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes. Boehringer Ingelheim and Lilly announced positive topline results from a phase 3 trial evaluating the ...
The European Commission (EC) has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and ...
The scientists found that two medications significantly reduce the risk of developing dementia in life. A new study, published in JAMA Neurology, finds that people with type 2 diabetes who take two ...
DEAR DR. ROACH: I am a 64-year-old male, and my A1C level has been averaging around 7.4% for a number of years. I was diagnosed diabetic at age 54. My doctor has been trying several combinations of ...
Maryland’s Prescription Drug Affordability Board says it has identified two diabetes drugs that could be made more affordable for residents based on a cost study by the state agency. During a meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback